Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago, IL. mRNA-4157 (V940) is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
The two abstract titles are:
- Abstract #LBA9515: Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab
Poster Discussion Session S406; Saturday, June 3 at 4:30 PM - 6:00 PM CDT
Presenter: Matteo S. Carlino, PhD, MBBS, FRACP - Abstract #LBA9503: Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial
Melanoma/Skin Cancers Oral Abstract Session; Monday, June 5 at 3:00 - 6:00 PM CDT
Presenter: Muhammad Adnan Khattak, PhD, FRACP, MBBS
Moderna Investor Event
Moderna will host a live webcast on Monday, June 5 from 6:00 - 7:00pm CDT, which will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.